Lauren Mifflin, Ph.D.

Lauren joined the Frazier Life Sciences team in 2023, where she focuses on Company Creation.

Lauren joined the Frazier Life Sciences team in 2023 and currently serves as a Principal of Company Creation and CEO/Co-Founder of Counterakt Therapeutics. Previously, she was the COO of Hillstar Bio, focused on developing biologics for autoimmune diseases. She is a board observer at Sudo Bio.

Prior to joining Frazier Life Sciences, Lauren was a venture partner at 82VS, the venture studio of Alloy Therapeutics. She helped to build biologics companies leveraging Alloy’s discovery capabilities, including co-founding a company creating T-cell receptor mimic (TCRm) therapeutics for solid tumor indications.

Before her time at 82VS, Lauren was a fellow and 4:59 operating associate at 5AM Ventures, focusing on evaluating investment opportunities and building new life sciences companies. In this capacity, Lauren worked with the founding team of Entrada Therapeutics and was a member of the founding team of Nido Biosciences, spanning strategy, operations and scientific discovery roles. Early in her career, Lauren was a health tech investor at Jump Capital and management consultant at Monitor Group/Monitor Deloitte.

Lauren received her Ph.D. from Harvard University where she studied the therapeutic effects of RIPK1 inhibitors on neuroinflammation in neurodegenerative diseases under Dr. Junying Yuan.